Efficacy model for mosquito stage transmission blocking vaccines for malaria
- 7 February 2008
- journal article
- research article
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 135 (13) , 1497-1506
- https://doi.org/10.1017/s0031182008000280
Abstract
SUMMARY: Vaccines that target antigens found on the mosquito stages of Plasmodium falciparum and Plasmodium vivax parasites are under development as transmission blocking vaccines. Antisera from vaccinated animals and humans are able to block oocyst development in artificially fed mosquitoes but it is not clear from these data what level of antibody response would be required for a useful vaccine in a field setting. This paper describes a mathematical model that takes into account the relationship between antibody levels and blocking of oocyst levels in artificial feeds, the distribution of antibody responses seen in human populations and the distribution of oocyst densities in infected mosquitoes in the field to calculate the levels of antibody in the host population that would be required to achieve a level of herd immunity in a vaccinated human population that would give an operationally useful level of transmission blocking. The model predicts that current formulations of Pfs25 are likely to achieve useful reductions in transmission when tested in human field trials.Keywords
This publication has 21 references indexed in Scilit:
- Mosquito stage, transmission blocking vaccines for malariaCurrent Opinion in Infectious Diseases, 2007
- Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titerMalaria Journal, 2007
- Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidatesVaccine, 2007
- Long-lasting and transmission-blocking activity of antibodies toPlasmodium falciparumelicited in mice by protein conjugates of Pfs25Proceedings of the National Academy of Sciences, 2007
- Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaVaccine, 2005
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialThe Lancet, 2004
- Malaria, Babesiosis, Theileriosis and Related DiseasesPublished by Springer Nature ,2004
- Malaria transmission-blocking vaccines—how can their development be supported?Nature Medicine, 2000
- A Cyclical Feeding Model for Pathogen Transmission and Its Application to Determine Vectorial Capacity from Vector Infection RatesJournal of Applied Ecology, 1990
- Estimation of Anopheline Survival Rate, Vectorial Capacity and Mosquito Infection Probability from Malaria Vector Infection Rates in Villages Near Madang, Papua New GuineaJournal of Applied Ecology, 1990